Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5628 primary lung cancer patients experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452–62.

Article  PubMed  Google Scholar 

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.

Article  PubMed  CAS  Google Scholar 

Saber A, van der Wekken A, Hiltermann TJN, Kok K, van den Berg A, Groen HJM. Genomic aberrations guiding treatment of non-small cell lung cancer patients. Cancer Treat Commun. 2015;4:23–33.

Article  Google Scholar 

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.

Article  PubMed  CAS  Google Scholar 

Wang C, Wang T, Lv D, Li L, Yue J, Chen HZ, et al. Acquired resistance to EGFR TKIs mediated by TGFbeta1/Integrin beta3 signaling in EGFR-mutant lung cancer. Mol Cancer Ther. 2019;18:2357–67.

Article  PubMed  CAS  Google Scholar 

Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38.

Article  PubMed  PubMed Central  Google Scholar 

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637–58.

Article  PubMed  CAS  Google Scholar 

Chhouri H, Alexandre D, Grumolato L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer. Cancers. 2023;15:504.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, et al. MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer. J Clin Invest. 2022;132:e150517.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5:695–08.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang B, Wang M, Zhang W, Xiao T, Chen C-H, Wu A, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019;14:756–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gonzalez AM, Bhattacharya R, deHart GW, Jones JC. Transdominant regulation of integrin function: mechanisms of crosstalk. Cell Signal. 2010;22:578–83.

Article  PubMed  CAS  Google Scholar 

Samarzija I, Dekanic A, Humphries JD, Paradzik M, Stojanovic N, Humphries MJ, et al. Integrin crosstalk contributes to the complexity of signalling and unpredictable cancer cell fates. Cancers. 2020;12:1910.

Cagnet S, Faraldo MM, Kreft M, Sonnenberg A, Raymond K, Glukhova MA. Signaling events mediated by alpha3beta1 integrin are essential for mammary tumorigenesis. Oncogene. 2014;33:4286–95.

Article  PubMed  CAS  Google Scholar 

Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O’Rear LD, Nashabi A, et al. The alpha(2)beta integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest. 2011;121:226–37.

Article  PubMed  CAS  Google Scholar 

Ramovs V, Te Molder L, Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. Matrix Biol. 2017;57-58:213–43.

Article  PubMed  CAS  Google Scholar 

Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu J, Cheng J, Zhang F, Luo X, Zhang Z, Chen S. Estrogen receptor alpha is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer. Ann Transl Med. 2020;8:993.

Article  PubMed  PubMed Central  Google Scholar 

Ryu J, Koh Y, Park H, Kim DY, Kim DC, Byun JM, et al. Highly expressed integrin-alpha8 induces epithelial to mesenchymal transition-like features in multiple myeloma with early relapse. Mol Cells. 2016;39:898–908.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lu X, Wan F, Zhang H, Shi G, Ye D. ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients. Tumor Biol. 2016;37:253–62.

Article  CAS  Google Scholar 

Kok-Sin T, Mokhtar NM, Ali Hassan NZ, Sagap I, Mohamed Rose I, Harun R, et al. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol Rep. 2015;34:22–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alanko J, Ivaska J. Endosomes: emerging platforms for integrin-mediated FAK signalling. Trends Cell Biol. 2016;26:391–8.

Article  PubMed  CAS  Google Scholar 

Mitra SK, Schlaepfer DD. Integrin-regulated FAK–Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–23.

Article  PubMed  CAS  Google Scholar 

Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004;165:1087–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005;17:542–7.

Article  PubMed  CAS  Google Scholar 

Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol. 2005;171:505–16.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mitra SK, Lim ST, Chi A, Schlaepfer DD. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene. 2006;25:4429–40.

Article  PubMed